Cover Image
市場調查報告書

全球胃食道逆流症 (GERD) 市場:2016年∼2020年

Global GERD Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 350481
出版日期 內容資訊 英文 84 Pages
訂單完成後即時交付
價格
Back to Top
全球胃食道逆流症 (GERD) 市場:2016年∼2020年 Global GERD Market 2016-2020
出版日期: 2016年01月20日 內容資訊: 英文 84 Pages
簡介

胃食道逆流症 (GERD) 是影響下部食道括約肌的慢性消化器官疾病,會造成胃酸和食物,液體在食道逆流,損傷食道的內薄膜。全球GERD市場預測在2016年∼2020年這段期間,年複合成長率將為2.85%。

本報告提供全球GERD市場相關調查分析,為您彙整產業概要,地區市場概要,推動市場的要素,市場課題,市場趨勢,主要供應商等資訊。

第1章 摘要整理

第2章 報告的範圍

第3章 市場調查的方法

  • 調查方法
  • 經濟指標

第4章 簡介

第5章 疾病概要

  • 疾病的理解
  • GERD的種類
  • 徵兆與症狀
  • 風險因素
  • 診斷
  • 治療
  • OTC藥的利用
  • 流行病學
  • 經濟負擔

第6章 開發平台·組合

第7章 市場的狀況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 市場區隔:藥物級

第9章 全球製酸藥市場

第10章 全球PPI藥市場

第11章 全球H2受體拮抗劑市場

第12章 市場區隔:給藥途徑

  • 口服
  • 非口服

第13章 市場區隔:劑型

  • 固體
  • 液體

第14章 各地區市場區隔

  • 全球GERD市場:各地區市場區隔
  • 南北美洲
  • 歐洲/中東/非洲
  • 亞太地區

第15章 推動市場的要素

  • 生活方式的因素
  • 過量攝取藥和營養補充品
  • 未滿足需求
  • GERD患者的增加
  • 成本效率好的OTC藥

第16章 促進要素的影響

第17章 市場課題

第18章 促進要素與課題的影響

第19章 市場趨勢

第20章 供應商狀況

  • 競爭模式

第21章 主要供應商分析

第22章 附錄

第23章 Technavio的其他報告

另紙一覽

目錄
Product Code: IRTNTR8134

About GERD Drugs

Gastroesophageal reflux disease (GERD) is a chronic digestive disorder that affects the lower esophageal sphincter (LES), the ring of muscle between the stomach and esophagus. It occurs when acidic stomach juices, or food and fluids flow back up into the food pipe (esophagus). The backwash irritates the lining of the esophagus and causes GERD. It affects all ages from infants to older adults. The symptoms of GERD include difficulty while swallowing (dysphagia), heartburn sensation, regurgitation or acid reflux, dry cough, sore throat, and chest pain.

GERD is believed to be caused by the overuse of certain medications, such as calcium channel blockers, nitrates and antihistamines. Unhealthy lifestyle factors such as smoking, drinking, slouching, consuming caffeinated drinks, eating large meals, and sleeping immediately after eating are some other typical causes for the occurrence of GERD. Pharmaceutical agents that are used to prevent complications and reduce morbidity in patients with GERD include antacids, H2 receptor antagonists, proton pump inhibitors (PPIs), and prokinetic agents.

Technavio's analysts forecast the global GERD drugs market to grow at a CAGR of 2.85% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global GERD drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of various drug classes used in the treatment of GERD.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • Europe

Technavio's report, Global GERD Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AstraZeneca
  • Eisai
  • GlaxoSmithKline
  • Johnson & Johnson
  • Takeda

Other Prominent Vendors

  • Ahn-Gook Pharmaceutical
  • Cancer Advances
  • CJ Cheil Jedang
  • Daewoong Pharmaceutical
  • Ironwood Pharmaceuticals
  • RaQualia Pharma
  • SFJ Pharmaceuticals Group
  • Sucampo Pharmaceuticals
  • Vecta Pharmaceuticals
  • Wockhardt
  • Yuhan
  • Zeria Pharmaceutical

Market driver

  • Unmet medical needs
  • For a full, detailed list, view our report

Market challenge

  • Increased preference for CAM
  • For a full, detailed list, view our report

Market trend

  • Increase in awareness about GERD
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings
  • Product profiles

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding the disease
  • Types of GERD
  • Signs and symptoms
  • Risk factors
  • Diagnosis
  • Treatment
  • Usage of OTC drugs in GERD
  • Epidemiology
  • Economic burden

PART 06: Pipeline portfolio

  • Information on pipeline candidates

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by drug class

PART 09: Global antacids market

  • Introduction
  • Market overview

PART 10: Global PPI drugs market

  • Introduction
  • Market overview

PART 11: Global H2 receptor antagonist drugs market

  • Introduction
  • Market overview

PART 12: Market segmentation by route of administration38

  • Oral
  • Parenteral

PART 13: Market segmentation by dosage form

  • Solid
  • Liquid

PART 14: Geographical segmentation

  • Global GERD drugs market segmentation by geography
  • GERD drugs market in the Americas
  • GERD drugs market in EMEA
  • GERD drugs market in APAC

PART 15: Market drivers

  • Lifestyle factors
  • Overuse of medicines and dietary supplements
  • Unmet medical needs
  • Increase in prevalence of GERD
  • Cost-effective OTC drugs

PART 16: Impact of drivers

PART 17: Market challenges

  • Increased preference for CAM
  • Adverse effects of drugs
  • Generic erosion
  • Counterfeit drugs

PART 18: Impact of drivers and challenges

PART 19: Market trends

  • Self-medication
  • Increase in awareness about GERD
  • Intense competition
  • Strategic alliances

PART 20: Vendor landscape

  • Competitive scenario

PART 21: Key vendor analysis

  • AstraZeneca
  • Eisai
  • GSK
  • Johnson & Johnson
  • Takeda
  • Other prominent vendors

PART 22: Appendix

  • List of abbreviations

PART 23: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Symptoms of pediatric GERD
  • Exhibit 03: GERD symptoms of older children and adolescents
  • Exhibit 04: Common risk factors for GERD
  • Exhibit 05: Dose, frequency, and average generic prices
  • Exhibit 06: Alternative treatment for GERD
  • Exhibit 07: Time line of the US FDA approved drugs for the treatment of GERD
  • Exhibit 08: Comparison between prescription and OTC drugs
  • Exhibit 09: Advantages and disadvantages of OTC drugs
  • Exhibit 10: Pipeline molecules for GERD
  • Exhibit 11: GERD clinical trials by development phase
  • Exhibit 12: GERD clinical trials by trial status
  • Exhibit 13: Global GERD drugs market 2015-2020 ($ billions)
  • Exhibit 14: Five forces analysis
  • Exhibit 15: Global GERD drugs market segmentation by drug class
  • Exhibit 16: Global GERD drugs market segmentation by drug class 2015
  • Exhibit 17: Global antacids market 2015-2020 ($ billions)
  • Exhibit 18: PPI sales in major non-US markets 2013 ($ millions)
  • Exhibit 19: Global PPIs market 2015-2020 ($ billions)
  • Exhibit 20: Global H2 receptor antagonists market 2015-2020 ($ billions)
  • Exhibit 21: Global GERD drugs market segmentation by route of administration
  • Exhibit 22: Global GERD drugs market segmentation by dosage form
  • Exhibit 23: Global GERD drugs market by geography 2015
  • Exhibit 24: Global GERD drugs market by geography 2015-2020 ($ billions)
  • Exhibit 25: GERD drugs market in the Americas 2015-2020 ($ billions)
  • Exhibit 26: GERD drugs market in EMEA 2015-2020 ($ billions)
  • Exhibit 27: GERD drugs market in APAC 2015-2020 ($ billions)
  • Exhibit 28: Impact of drivers
  • Exhibit 29: Common side effects associated with Nexium, Prontonix, Aciphex, and other heartburn medications
  • Exhibit 30: Impact of drivers and challenges
  • Exhibit 31: Drugs that underwent Rx-to-OTC switch in the US
  • Exhibit 32: AstraZeneca: Business segmentation by revenue 2014
  • Exhibit 33: AstraZeneca: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 34: AstraZeneca: Geographical segmentation by revenue 2014
  • Exhibit 35: AstraZeneca: YoY revenue growth of Nexium 2012-2014 ($ billions)
  • Exhibit 36: AstraZeneca: YoY revenue growth of Losec 2012-2014 ($ millions)
  • Exhibit 37: AstraZeneca: YoY revenue growth of Vimovo 2012-2014 ($ millions)
  • Exhibit 38: AstraZeneca: Key takeaways
  • Exhibit 39: Eisai: Business segmentation by revenue 2014
  • Exhibit 40: Eisai: Business segmentation by revenue 2013 and 2014 ($ millions)
  • Exhibit 41: Eisai: YoY revenue growth of Pariet 2011-2014 ($ billions)
  • Exhibit 42: Eisai: Key takeaways
  • Exhibit 43: GSK: Business segmentation by revenue 2014
  • Exhibit 44: GSK: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 45: GSK: Geographical segmentation by revenue 2014
  • Exhibit 46: GSK: Key takeaways
  • Exhibit 47: Johnson & Johnson: Business segmentation by revenue 2014
  • Exhibit 48: Johnson & Johnson: Business segmentation 2013 and 2014 by revenue ($ billions)
  • Exhibit 49: Johnson & Johnson: Geographical segmentation by revenue 2014
  • Exhibit 50: Johnson & Johnson: Key takeaways
  • Exhibit 51: Takeda: Business segmentation by revenue 2014
  • Exhibit 52: Takeda: Business segmentation by revenue 2013 and 2014 ($ millions)
  • Exhibit 53: Takeda: Geographical segmentation by revenue 2014
  • Exhibit 54: Takeda: YoY revenue growth of Prevacid 2012-2014 ($ billions)
  • Exhibit 55: Takeda: YoY revenue growth of Dexilant 2012-2014 ($ billions)
  • Exhibit 56: Takeda: YoY revenue growth of Protonix 2012-2014 ($ billions)
  • Exhibit 57: Takeda: Key takeaways
Back to Top